[Prognostic value of rectal cancer regression after preoperative chemoradiation therapy].

Despite the international experience enriched in the number of observations of combination treatment in patients with rectal cancer, many issues remain to be the subject-matter of the discussion. This also applies to the estimation of the value of tumor regression after neoadjuvant chemoradiation therapy in order to develop indications for sphincter-sparing operations depending on the site of a tumor in the organ and their impact on long-term treatment results. The authors have gained experience with combination treatment in 157 patients with rectal cancer (T2-4 N0-2 M0) receiving neoadjuvant chemoradiation therapy in a cumulative radiation dose of 39.

[Decrease of the number of involved lymph nodes after preoperative chemoradiotherapy in rectal carcinoma].

The total of 296 T3-4NO-2 Federal Coloproctology Science Center colon cancer patients received treatment since 2004 to 2011, 165 patients (main group) also received treatment (pre- and postoperative irradiation, surgery, adjuvant chemotherapy) in P.A.Herzen State Clinical Research Center for Oncology.

[Influence of a total focal dose of preoperative chemoradiotherapy on direct results of treatment of rectal cancer].

An analysis of complex treatment of 154 patients with T2-4N0-2 stage rectal cancer is presented who were given preoperative chemoradiotherapy in regimen of dynamic functioning with total focal dose 39.5 Gy (71 patients of the first group) and 47 Gy (83 patients of the second group) using 5-fluororacil and cisplatin. A multivariant analysis has demonstrated a reliably increased frequency of total and close to total regressions of rectal cancer (1-2 stage by Mandard) in the second group as compared with reduced duration of the operative intervention the 1st group (43.

[Effect of the duration of time between chemo-radiotherapy and surgical intervention on the results of the combined treatment of rectal cancer].

Complex treatment included preoperative radiochemotherapy (fractionated TTD of 47 Gy), 5-FU 2.75-3.5 g, cisplatin 90 mg, surgery and postoperative adjuvant chemotherapy (XELOX).